Senior resident 5 lll rd year P.G. student

Similar documents
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

Comparative Evaluation of Diagnostic Efficacy of Serum. Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome

Polycystic Ovary Syndrome

Reproduction. AMH Anti-Müllerian Hormone. Analyte Information

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Polycystic Ovarian Syndrome (PCOS) LOGO

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

A STUDY OF CLINICAL PARAMETERS IN THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME Soumya Ranjan Panda 1, K. Durgavati 2, Santhosh Kumar Sahu 3

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

Overview of Reproductive Endocrinology

Polycystic Ovary Syndrome

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

PCOS and Obesity DUB is better treated by OCPs

SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY

Endocrine control of female reproductive function

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

International Journal of Pharma and Bio Sciences ENDOCRINE MARKERS AND DECLINE IN REPRODUCTIVE POTENTIAL OF WOMEN ABSTRACT

THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4

UNDERSTANDING PCOS AND ITS DIAGNOSIS

Clinical study of polycystic ovarian syndrome (PCOS) in tertiary care centre

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai

Reproductive FSH. Analyte Information

Ontogeny of the new hypo-androgenic PCOS phenotype

JMSCR Vol 05 Issue 05 Page May 2017

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

WHY INVESTIGATE FOR INFERTILITY

The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome

Polycystic Ovary Syndrome

EXCEPTIONAL DIAGNOSTICS FOR REPRODUCTIVE DISEASE STATE MANAGEMENT. Anti-Müllerian Hormone (AMH)

Female Reproductive Endocrinology

Polycystic Ovary Syndrome (PCOS):

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

INFERTILITY CAUSES. Basic evaluation of the female

ANTI-MÜLLERIAN HORMONE (AMH) AS A USEFUL MARKER IN DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME

Correlation of Anti-Mullerian Hormone with clinical, hormonal and ultrasonographic parameters in PCOS and normo-ovulatory women

The Relation of Serum Anti-Mullerian Hormone with Polycystic Ovary Syndrome: Correlation with Clinical and Hormonal Parameters

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page

Neil Goodman, MD, FACE

ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME

X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.

JMSCR Vol 06 Issue 09 Page September 2018

JMSCR Vol 05 Issue 04 Page April 2017

Test Briefing on Hormonal Disorders and Infertility

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour

Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study

Evaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis

Original Research Article

Prof.Dr. Nabil Lymon Head of Internal Medicine Department

Thesis. Mahmoud Sedki Yassin (MsC) Cairo University. Under supervision of

Serum anti-mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism

Clinical Profile Polycystic Ovarian Syndrome Cases

Reproductive Health and Pituitary Disease

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

Estimation of serum 25 hydroxy vitamin D level and its correlation with metabolic and endocrine dysregulation in women with PCOS

International Journal of Current Medical And Applied Sciences.vol.1. Issue: 1, 2013, PP 11-15

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

Hyperandrogenism. Dr Jack Biko. MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany)

Abnormal Uterine Bleeding Case Studies

PCOS. Reproductive Gynaecology and Infertility. Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University

13 th Annual Women s Health Day PCOS. Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Antim ullerian hormone and polycystic ovary syndrome

Age-Specific Serum Anti-Mullerian Hormone and Follicle Stimulating Hormone Concentrations in Infertile Iranian Women

Assisted Reproductive. Technologies: Present and. Future

Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

Endocrinology of the Female Reproductive Axis

Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

Anti-Mullerian hormone (AMH) as predictor of ovarian reserve

Serum müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome

Case. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?

Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI

Approach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD

Pregnancy outcome in women with polycystic ovary syndrome

UPDATE: Women s Health Issues

Age specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation

Department of Obstetrics and Gynecology, Benha Faculty of Medicine, Benha University, Egypt

Achieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center

INFERTILITY: DIAGNOSIS, WORKUP AND MANAGEMENT FOR THE COMMUNITY PHYSICIAN

Nature and Science 2017;15(8)

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Transcription:

International Journal of scientific research and management (IJSRM) Volume 4 Issue 06 Pages 4253-4261 2016 Website: www.ijsrm.in ISSN (e): 2321-3418 An Observational Cross Sectional Study Of Serum Anti-Mullerian Hormone In PCOS Infertile Women Meena Veena, Khuteta Sushila, Rajoria Lata, Beniwal Devendra, Kuree Amrawatin, Bariha Kalpana ABSTRACT 1 lll rd year P.G. student 2 Professor and Unit Head 3 Professor and Head of Department 4 Senior resident 5 lll rd year P.G. student 6 lll rd year P.G. student Department of Obstetrics and Gynaecology S.M.S. Medical College Jaipur-302012(Rajasthan) Email:- mahar.veena@gmail.com OBJECTIVE: To evaluate the role of serum Anti-Mullerian Hormone in PCOS infertile women. METHOD: A total of 64 Polycystic ovary syndrome infertile women of 18-35 years age, according to Rotterdam Criteria (2003) were observed for role of serum Anti-Mullerian Hormone in PCOS infertile women. Serum levels of LH, FSH, testosterone, fasting insulin and AMH were measured in the early follicular phase (day 3 4) of natural cycle or progestin-induced withdrawal bleeding (in PCOS); together with TVS for detection of the number of small follicles (<10 mm) and calculation of ovarian volume. RESULTS: Serum AMH was significantly higher in the PCOS infertile women. 61 patients (95.3 percent) have serum AMH level >10ng/ml.59 patients (92.2 percent) have number of follicles >12 (size <10mm) and higher ovarian volume. Serum Testosterone level >70 pg/dl in 27 patients (42.2 percent), LH/FSH ratio >2 in 38 patients (59.4 percent),34 (53.1 percent) patients have insulin resistance. Acne in 53(82.8 percent),hirsutism in 42 (65.6 percent), Acanthosis nigricans in 8 (12.5 percent) patients, irregular menstrual cycle & oligo or amenorrhoea in 58 (90.6 percent) patients and BMI >25kg/m 2 in 41(64 percent) patients. CONCLUSION: Serum AMH is a good marker of Ovarian reserve. Serum AMH level two or three times the normal amount, is a good indicator of PCOS and infertility. It can be used as an alternative diagnostic criteria for PCOS patients and may be used as a marker for the extent or severity of the disease in PCOS infertile female.amh positively correlate to LH, LH/FSH, and number of follicles <10mm and ovarian volume. No correlation between AMH and age, BMI and fasting insulin level in PCOS infertile women. KEYWORDS: PCOS, AMH, AFC, OVARIAN VOLUME, LH/FSH,BMI Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4253

INTRODUCTION Infertility is a major gynaecological problem. Polycystic ovary syndrome (PCOS) is a one of the most common endocrine disorders in women of childbearing age. Polycystic ovary syndrome (PCOS), also called hyperandrogenic anovulation (HA) or Stein-Leventhal syndrome is the most common cause of oligo-ovulation and anovulation both in the general population and among women presenting with infertility. It is characterized by anovulation manifested as oligomenorrhea or amenorrhea, elevated levels of androgens & Leutinizing hormone & polycystic ovaries by ultrasound. [1] Its genetic origin are polygenic and or multifactorial. [2] Incidence of PCOS: 5 to 10% of women of reproductive age. CLINICAL FEATURES OF PCOS - Young woman, Central obesity- BMI >30kg/cm2 & Waist line >35, Oligomenorrhoea/amenorrhoea, Infertility, Hirsutism, Acanthosis nigracans due to insulin resistance (Thick pigmented skin over the nape of neck, inner thigh and axilla). Criteria used for diagnosis of PCOS:- [3] 1. NIH Criteria (1990) 2. Rotterdam Criteria (2003) 3. Androgen Excess and PCOS Society (AE- PCOS) Criteria (2006) ANTI-MULLERIAN HORMONE:- Anti-Müllerian hormone also known as AMH is a protein that, in humans, is encoded by the AMH gene. It inhibits the development of the Müllerian ducts (paramesonephric ducts) in the male embryo. It is named after Johannes Peter Müller. The dimeric glycoprotein Anti-mullerian hormone (AMH) is a member of transforming - growth factor & plays regulatory role in male sex differentiation. AMH is produced by sertoli cells of fetal testis & induces regression of mullerian duct. In females AMH produced by granulosa cells from preantral and small antral follicles. Normal range of AMH - 3.64 + 1.51ng/ml [4, 5] AMH is a strong indicator of a woman's ovarian reserve (OR). AMH has an inhibitory effect on the primordial follicle recruitment as well as on the responsiveness of growing follicles to FSH. The concentration of AMH higher in small follicles, then decreased to low or undetectable in follicles >9mm. AMH two or three times the normal amount (10.0 + 2.28ng/ml), is a good indication of PCOS and infertility. Women with many small follicles, such as those with polycystic ovaries have high AMH hormone values and women that have few Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4254

remaining follicles and those that are close to menopause have low anti-mullerian hormone levels. With increasing female age, the size of their pool of remaining microscopic follicles decreases. Likewise, their blood AMH levels and the number of ovarian antral follicles visible on ultrasound also decrease. AMH also inhibits aromatase activity, suggesting that AMH contributes to the severity of PCOS. AMH IN PCOS Distinctive feature of PCOS is failure of follicular maturation despite initial recruitment, resulting in anovulation and accumulation of pre-antral & small antral follicles, which contributes significantly to production of AMH. (6,7) AMH also inhibits aromatase activity, suggesting that AMH contributes to the severity of PCOS. (8) The value of the AMH generally correlates with the number of functional primordial and antral follicles remaining in the ovary. Generally, the higher the AMH, the more healthy follicles are in the ovary. AMH blood levels are thought to reflect the size of the remaining egg supply or ovarian reserve. AMH positively correlate to LH, LH/FSH, and number of follicles <10mm and negatively correlate to FSH. No correlation between AMH and age, BMI, estradiol or fasting insulin. Testosterone and androstenedione positively correlate to AMH in the PCOS group. AMH production is highest in preantral and small antral stages of development. Production decreases and then stops as follicles grow. There is almost no AMH made in follicles over 9 mm.therefore, the levels are fairly constant and the AMH test can be done on any day of the woman s cycle. SERUM AMH TEST USED IN In Women 1. PCOS- high AMH level-due to increase number of preantral and small antral follicles. 2. Menopause-. A decreasing level and/or significant decline in AMH may signal the imminent onset of menopause 3. Ovarian cancer - a decrease in AMH indicates a response to treatment and an increase may indicate cancer recurrence. 4. In vitro fertilization- higher AMH levels are associated with greater chance of live birth after IVF, even after adjusting for age 5. General fertility assessment-as it provides a guide to ovarian reserve In Infant Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4255

1. Absent or dysfunctional testicles 2. Ambiguous genitalia- due to lack of male hormones AIMS & OBJECTIVE:- To evaluate the role of serum Anti-Mullerian Hormone in PCOS infertile women. METHOD:- This Observational Cross sectional study was carried out on PCOS infertile women attending the OPD in Mahila chikitshalya, SMS Medical college Jaipur. The inclusion criteria were: age between 18 and 35 years, both ovaries present, no previous ovarian operation, adequate visualization of ovaries on transvaginal sonography, and no current hormonal therapy. Women with other causes of endocrinological abnormalities such as primary hyperprolactinemia, thyroid dysfunction, Cushing s syndrome and congenital adrenal hyperplasia were excluded from the PCOS study group. The diagnostic criteria used to identify the presence of PCOS were according to the criteria proposed at the Rotterdam revised consensus meeting [9].A total of 64 Polycystic ovary syndrome infertile women were observed for role of serum Anti-Mullerian Hormone in PCOS infertile women. Serum levels of LH, FSH, testosterone, fasting insulin and AMH were measured in the early follicular phase (day 3 4) of natural cycle or progestin-induced withdrawal bleeding (in PCOS); together with TVS for detection of the number of small follicles (<10 mm) and calculation of ovarian volume. FSH Normal cutoff -<10 miu/ml LH - Normal cutoff -<10 miu/ml Total testosterone - Normal cutoff -<70 ng/dl Prolactin - Normal cutoff -<35 ng/dl AMH - Normal range - 3.64 +1.51 ng/ml RESULTS:- Present study was conducted in 64 PCOS infertile women, out of which 62.5 per cent women belong to primary infertility and 37.5 per cent belong to secondary infertility. 73.4 percent patients were from Urban area and 26.6 percent patients were from rural area. The less percentage of rural patients may be due to difference in catchment area of hospital, lack of awareness. In present study most of PCOS infertile women were from Upper-Middle socioeconomic class (class II) of Kuppuswamy socio economic classification (1985). 61 percent patients belonged to 21-25 years age group and 36 percent patients belonged to 26-30 years age group. Mean age of infertility was 24.59 years. In our study 64 percent patients have Body mass index >25 and 36 percent patients Body mass index <25. Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4256

57.8 percent patients have serum Testosterone level >70 pg/dl. Maximum number (95.3 percent) of patients in our study have serum Anti- Mullerian Hormone level >10 ng/dl. 59.4 percent patients have LH/FSH ratio >2 and 40.6 percent patients have LH/FSH ratio <2. In our study 82.8 percent patients have features of Acne and features of hisuitism present in 65.6 percent patients. 12.5 percent patients have features of Acanthosis nigricans. Menstrual cycle irregularity and oligomenorrhoea/ amenorrhoea present in 90.6 percent patients. 53.1 percent PCOS infertile patients have insulin resistance and no insulin resistance in 46.9 percent patients. In our study on Ultra-Sonography >12 follicles (<10 mm) present in 92.2 percent patients in one ovary. These follicles arrange on periphery of both ovaries as neck-lace appearance. These follicles secrete more amount of Anti-mullerian hormone. Number of follicles (<10 mm) more in PCOS patients so serum AMH level high in these patients. AMH, produced from the granulosa cells of the primary follicles, reaches maximum expression in the preantral follicles, with lesser secretion by the greater antral follicles Ovarian volume (>10 cm 3 ) present in maximum number of patients. Volume of correlate to number of follicles (<10mm size).number of follicles if more, higher the ovarian volume. DISCUSSION- Present study of 64 cases on PCOS infertile women was conducted in Mahila Chikitsalya, Sanganeri Gate, Jaipur,an affiliate of Department of obstetrics and Gynaecology, S.M.S. Medical College and attached hospitals, during the period March 2014 to February 2015. In our study Maximum PCOS infertile patients have age between 21-25 years. Mean age of PCOS infertile female-24.59 years that is almost similar to studies done by Shehla Haider (2011) et al (10). Hirsuitism is a common feature of PCOS. 42 (65.6 per cent) patients had features of hirsuitism and 64 percent patients had features of hirsuitism in study done by Soumya Ranjan Panda et al (11). (Table no.1) Table no. 1 Distribution of patients according to different parameters Parameters No. of % cases Residence Rural 17 26.56 Urban 47 73.44 BMI <25 23 36 >25 41 64 Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4257

Type of Primary 40 62.5 infertility Secondary 24 37.5 Menstrual Regular 6 9.4 cycle Irregular & 58 90.6 oligomenorrhoea Acne 53 82.8 cases LH/FSH <2 26 40.6 >2 38 59.4 Testosterone <70 37 57.8 (pg/dl) >70 27 42.2 Insulin Present 34 53.1 resistance Absent 30 46.9 Hirsutism 42 65.6 Acanthosis Nigricans 8 12.5 83 percent patients had features of Acne in our study that was almost similar to study done by Shehla haider (2011). The study shows that 12.5 per cent patients had features of Acanthosis Nigricans. Soumya Ranjan Panda et al shows in their study.16 percent patients had features of Acanthosis Nigricans.90 per cent patients had features of Oligomenorrhoea in our study that was almost similar (92 percent) to study done by Esmaeilzadeh S et al (12). In maximum cases of PCOS LH/FSH ratio >2. In our study 59 per cent patients had > 2 LH/FSH ratio that is almost similar to study done by Sharquie K E (2007) et al (13). (Table no. 2) Table no. 2 In this study 53.1 per cent patients had insulin resistence that is almost similar (53.1 percent) to study done by Morey Schachter (2003) et al. The normal range of total testosterone for women is 15-70 (ng/dl). A total testosterone level > 70 ng/dl was regarded as indicating hyper androgenemia. In our study 42.2 per cent patients had increased (>70 ng/dl) serum testosterone level but 42 percent in study done by Sachan Rekha (2013) et al (14). (Table no.2) Maximum PCOS patients have higher level of AMH.Normal range of AMH 3.64 + 1.51 ng/ml. In our study 95.3 per cent patients had serum AMH value >10 ng/ml that is almost similar to study done by Tal R et al (15). In their study, 97 per cent patients had serum AMH value >10 ng/ml. (Table no. 3) Table no. 3 Distribution of patient according to AMH level Distribution of patient according to LH/FSH, Testosterone & insulin resistance Range AMH of (ng/ml No. of Patient % Parameters No. of % ) Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4258

0-5 1 1.6 5-10 2 3.1 10-15 43 67.2 15-20 15 23.4 >20 3 4.7 Total 64 100 According to Rotterdem criteria for PCOS ultra sound finding positive (>12 follicles size <10 mm in single ovary). In our study 92.2 per cent patients had number of follicles >12 in PCOS infertile women by Ultra-sound finding but 91 percent in study done by Sahar Sajjad (2014)et al (16) and 89 percent in study done by Esmaeilzadeh S et al. (Table no. 4) Table no. 4 Distribution of patient according to no. of Follicles NO. OF NO. CASES PERSENTAGE FOLLICLE counts (<10 mm) 0-12 5 7.8 12-20 14 21.9 21-25 35 54.7 26-30 8 12.5 >30 2 3.1 Total 64 100 (Mean AFC -20.94) In our study 64 per cent patients had Body mass index >25 which was similar (64 percent) to study done by Sachan Rekha (2013) et al. 62.5 per cent cases were of primary infertility and 37.5 percent belonged to secondary infertility Table no.5 Distribution of patient according to ovarian volume Ovarian volume ( cm 3 ) No. of patient % 0-10 0-11-20 5 7.8 21-30 31 48.4 30-40 26 40.6 >40 2 3.1 Total 64 100 (Mean ovarian volume -28.26 cm3) CONCLUSION:- Hence on concluding the present study, serum AMH is a good marker of Ovarian reserve. Serum AMH level two or three times the normal amount is a good indicator of PCOS and infertility. It can be used as an alternative diagnostic criteria for PCOS patients and may be used as a marker for the extent or severity of the disease in PCOS infertile female. Elevated AMH serum levels in PCOS patients might indicate an increased ovarian reserve. There is a strong positive correlation between serum Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4259

AMH level and AFC. The use of AMH combined with AFC may improve ovarian reserve evaluation. AMH positively correlate to LH, LH/FSH, and number of follicles <10mm cycle duration, the serum androgens levels and negatively correlate to FSH. No correlation between AMH and age, BMI and fasting insulin level in PCOS infertile women. Plasma AMH assessments are superior to FSH in identifying women with reduced ovarian reserve. AMH can be measured on any day of the cycle, because there are no fluctuations and it has low cyclical inter individual. BIBLIOGRAPHY:- 1. Leon Speroff. Clinical gynecologic endocrinology and infertility. Lippincott Williams. 2005;12:485 513 2. Berek's Novak's Chapter 31 Endocrine disorders. page 1075. 3. Leon Speroff. Clinical gynecologic endocrinology and infertility. 4. Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, Wilson C, et al. Antimullerian hormone: the Jost factor. Recent ProgHorm Res. 1993;48:1 59 5. Lee MM, Donahoe PK. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev. 1993;14:152 164 6. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normo-ovulatory and anovulatory women of reproductive age. J ClinEndocrinolMetab. 2004;89:318 323 7. Pigny P, Merlen E, Robert Y, Cortet- Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J ClinEndocrinolMetab. 2003;88:5957 5962 8. Di Clemente N, Ghaffari S, Pepinsky RB, Pieau C, Josso N, Cate RL, et al. A quantitative and interspecific test for biological activity of anti-mullerian hormone: the fetal ovary aromatase assay. Development. 1992;114:721 727 9. The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19, 41-47.doi:10.1093/humrep/deh098 10. Shehla Haider,1 Nighat Manan,1 Ayesha Khan2 and Masood A Qureshi1Prevalence Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4260

of Elevated Luteinizing Hormone (LH)/Follicle Stimulating Hormone (FSH) Ratio in Polycystic Ovary Syndrome (PCOS) Women Among Local Population 11. Soumya Ranjan Panda, K. Durgavati, Santhosh Kumar Sahu (2014), Department of Obstetrics & Gynaecology, KIMS & RF, Amalapurm. A study of clinical parameters in the diagnosis of polycystic ovarian syndrome 12. Esmaeilzadeh S, Andarieh MG1, Ghadimi R, Delavar MA.- Body mass index and gonadotropin hormones (LH & FSH) associate with clinical symptoms among women with polycystic ovary syndrome. 13. Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al- Bahar AJ, Al-Nuaimy AA. Saudi Med J.2007; (7):1039-43 Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. 14. Sachan Rekha, M. L. Patel, Gupta Pooja, Diwakar Amita, Sachan Pushplata and S. M. Natu. Department of Obstetrics and Gynaecology, C. S. M. Medical University, UP-226003, C-28, Sec-J, Aliganj, Lucknow- 226024, India. 15. Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B3.Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. 16. Sahar Sajjad1, Saeed Alam2, Wajiha Mahjabeen3, 2014:3 (2): 5861 Association of Clinical Features with Obesity and Gonadotropin Levels in Women with Polycystic Ovarian Syndrome Meena Veena, IJSRM volume 4 issue 6 June 2016 [www.ijsrm.in] Page 4261